fda glp-1 safety warning september 2025 semaglutide news october 8, 2025: launches an import alert listing safe manufacturers – Partnership for Safe Medicines FDA alerts health care providers, – Wegovy HD Safety Alerts, Recalls

The primary endpoint in the CV safety outcome trials was a composite of CV death, non-fatal myocardial infarct, and non-fatal stroke (and unstable angina requiring hospitalization in TECOS)

Trescientos cuarenta y nueve participantes recibieron citicolina oral (1,000 mg/da) o ningn tratamiento durante nueve meses

Some other studies suggest that GLP-1s have this potential, but more research is needed to clarify the effects of Zepbound and other similar weight loss medications, says Mikulik

However, medical and nutrition experts criticized the reports reliance on the Nova system to classify UPFs, which was developed by one of the series co-authors

References Alliance for Pharmacy Compounding